FIELD: biotechnology.
SUBSTANCE: isolated antibody to PD-L1 and its antigen-binding fragment, characterized by amino acid sequences of hypervariable regions (HVR) in the heavy chain and light chain variable regions, are proposed. In addition, an isolated nucleic acid encoding the antibody; an expression vector; a host cell and a method for production of an antibody or an antigen-binding fragment thereof are described. Also a composition comprising an effective amount of the antibody to PD-L1 or the antigen-binding fragment; a product of manufacture comprising a container with a therapeutically effective amount of the composition; and methods for malignant tumour and infection treatment are considered.
EFFECT: invention can find further application in therapy.
60 cl, 11 dwg, 4 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING AND VEGF ANTAGONISTS | 2013 |
|
RU2689760C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
| H7N9 INFLUENZA A THERAPY | 2015 |
|
RU2682049C2 |
| METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
| ANTIBODIES AGAINST NOTCH2 AND METHODS FOR APPLICATION THEREOF | 2009 |
|
RU2580029C2 |
| ANTI-BV8 ANTIBODIES AND USING THEM | 2010 |
|
RU2559542C2 |
| METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| OX40L ANTIBODIES AND METHODS FOR USING | 2006 |
|
RU2426744C2 |
| APOPTOTIC ANTIBODIES AGAINST IgE | 2008 |
|
RU2500686C2 |
